Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis : the EASI-SWITCH RCT
Background: Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy.
Objectives: To establish the clinical and cost effectiveness of early switch to oral antibiotics in patients with neutropenic sepsis at low risk of infective complications.
Design: A randomised, multicentre, open-label, allocation concealed, non-inferiority trial to establish the clinical and cost effectiveness of early oral switch in comparison to standard care.
Setting: Nineteen UK oncology centres.
Participants: Patients aged 16 years and over receiving systemic anticancer therapy with fever (≥ 38°C), or symptoms and signs of sepsis, and neutropenia (≤ 1.0 × 109/l) within 24 hours of randomisation, with a Multinational Association for Supportive Care in Cancer score of ≥ 21 and receiving intravenous piperacillin/tazobactam or meropenem for < 24 hours were eligible. Patients with acute leukaemia or stem cell transplant were excluded.
Intervention: Early switch to oral ciprofloxacin (750 mg twice daily) and co-amoxiclav (625 mg three times daily) within 12-24 hours of starting intravenous antibiotics to complete 5 days treatment in total. Control was standard care, that is, continuation of intravenous antibiotics for at least 48 hours with ongoing treatment at physician discretion.
Main outcome measures: Treatment failure, a composite measure assessed at day 14 based on the following criteria: fever persistence or recurrence within 72 hours of starting intravenous antibiotics; escalation from protocolised antibiotics; critical care support or death.
Results: The study was closed early due to under-recruitment with 129 patients recruited; hence, a definitive conclusion regarding non-inferiority cannot be made. Sixty-five patients were randomised to the early switch arm and 64 to the standard care arm with subsequent intention-to-treat and per-protocol analyses including 125 (intervention n = 61 and control n = 64) and 113 (intervention n = 53 and control n = 60) patients, respectively. In the intention-to-treat population the treatment failure rates were 14.1% in the control group and 24.6% in the intervention group, difference = 10.5% (95% confidence interval 0.11 to 0.22). In the per-protocol population the treatment failure rates were 13.3% and 17.7% in control and intervention groups, respectively; difference = 3.7% (95% confidence interval 0.04 to 0.148). Treatment failure predominantly consisted of persistence or recurrence of fever and/or physician-directed escalation from protocolised antibiotics with no critical care admissions or deaths. The median length of stay was shorter in the intervention group and adverse events reported were similar in both groups. Patients, particularly those with care-giving responsibilities, expressed a preference for early switch. However, differences in health-related quality of life and health resource use were small and not statistically significant.
Conclusions: Non-inferiority for early oral switch could not be proven due to trial under-recruitment. The findings suggest this may be an acceptable treatment strategy for some patients who can adhere to such a treatment regimen and would prefer a potentially reduced duration of hospitalisation while accepting increased risk of treatment failure resulting in re-admission. Further research should explore tools for patient stratification for low-risk de-escalation or ambulatory pathways including use of biomarkers and/or point-of-care rapid microbiological testing as an adjunct to clinical decision-making tools. This could include application to shorter-duration antimicrobial therapy in line with other antimicrobial stewardship studies.
Trial registration: This trial is registered as ISRCTN84288963.
Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 13/140/05) and is published in full in Health Technology Assessment; Vol. 28, No. 14. See the NIHR Funding and Awards website for further award information.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Health technology assessment (Winchester, England) - 28(2024), 14 vom: 09. März, Seite 1-101 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coyle, Vicky [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 25.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3310/RGTP7112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370016491 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370016491 | ||
| 003 | DE-627 | ||
| 005 | 20240425233237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3310/RGTP7112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370016491 | ||
| 035 | |a (NLM)38512064 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coyle, Vicky |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis |b the EASI-SWITCH RCT |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy | ||
| 520 | |a Objectives: To establish the clinical and cost effectiveness of early switch to oral antibiotics in patients with neutropenic sepsis at low risk of infective complications | ||
| 520 | |a Design: A randomised, multicentre, open-label, allocation concealed, non-inferiority trial to establish the clinical and cost effectiveness of early oral switch in comparison to standard care | ||
| 520 | |a Setting: Nineteen UK oncology centres | ||
| 520 | |a Participants: Patients aged 16 years and over receiving systemic anticancer therapy with fever (≥ 38°C), or symptoms and signs of sepsis, and neutropenia (≤ 1.0 × 109/l) within 24 hours of randomisation, with a Multinational Association for Supportive Care in Cancer score of ≥ 21 and receiving intravenous piperacillin/tazobactam or meropenem for < 24 hours were eligible. Patients with acute leukaemia or stem cell transplant were excluded | ||
| 520 | |a Intervention: Early switch to oral ciprofloxacin (750 mg twice daily) and co-amoxiclav (625 mg three times daily) within 12-24 hours of starting intravenous antibiotics to complete 5 days treatment in total. Control was standard care, that is, continuation of intravenous antibiotics for at least 48 hours with ongoing treatment at physician discretion | ||
| 520 | |a Main outcome measures: Treatment failure, a composite measure assessed at day 14 based on the following criteria: fever persistence or recurrence within 72 hours of starting intravenous antibiotics; escalation from protocolised antibiotics; critical care support or death | ||
| 520 | |a Results: The study was closed early due to under-recruitment with 129 patients recruited; hence, a definitive conclusion regarding non-inferiority cannot be made. Sixty-five patients were randomised to the early switch arm and 64 to the standard care arm with subsequent intention-to-treat and per-protocol analyses including 125 (intervention n = 61 and control n = 64) and 113 (intervention n = 53 and control n = 60) patients, respectively. In the intention-to-treat population the treatment failure rates were 14.1% in the control group and 24.6% in the intervention group, difference = 10.5% (95% confidence interval 0.11 to 0.22). In the per-protocol population the treatment failure rates were 13.3% and 17.7% in control and intervention groups, respectively; difference = 3.7% (95% confidence interval 0.04 to 0.148). Treatment failure predominantly consisted of persistence or recurrence of fever and/or physician-directed escalation from protocolised antibiotics with no critical care admissions or deaths. The median length of stay was shorter in the intervention group and adverse events reported were similar in both groups. Patients, particularly those with care-giving responsibilities, expressed a preference for early switch. However, differences in health-related quality of life and health resource use were small and not statistically significant | ||
| 520 | |a Conclusions: Non-inferiority for early oral switch could not be proven due to trial under-recruitment. The findings suggest this may be an acceptable treatment strategy for some patients who can adhere to such a treatment regimen and would prefer a potentially reduced duration of hospitalisation while accepting increased risk of treatment failure resulting in re-admission. Further research should explore tools for patient stratification for low-risk de-escalation or ambulatory pathways including use of biomarkers and/or point-of-care rapid microbiological testing as an adjunct to clinical decision-making tools. This could include application to shorter-duration antimicrobial therapy in line with other antimicrobial stewardship studies | ||
| 520 | |a Trial registration: This trial is registered as ISRCTN84288963 | ||
| 520 | |a Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 13/140/05) and is published in full in Health Technology Assessment; Vol. 28, No. 14. See the NIHR Funding and Awards website for further award information | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AMBULATORY CARE | |
| 650 | 4 | |a AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION | |
| 650 | 4 | |a CIPROFLOXACIN | |
| 650 | 4 | |a COST–BENEFIT ANALYSIS | |
| 650 | 4 | |a DURATION OF THERAPY | |
| 650 | 4 | |a FEBRILE NEUTROPENIA | |
| 650 | 4 | |a GUIDELINE ADHERENCE | |
| 650 | 4 | |a HEALTH RESOURCES | |
| 650 | 4 | |a PATIENT PREFERENCE | |
| 650 | 4 | |a PIPERACILLIN | |
| 650 | 4 | |a PRAGMATIC CLINICAL TRIALS AS TOPIC | |
| 650 | 4 | |a RISK FACTORS | |
| 650 | 4 | |a SEPSIS | |
| 650 | 4 | |a TAZOBACTAM DRUG COMBINATION | |
| 650 | 4 | |a TREATMENT FAILURE | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Forde, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Agus, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Rosemary |e verfasserin |4 aut | |
| 700 | 1 | |a Chau, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Mike |e verfasserin |4 aut | |
| 700 | 1 | |a Doran, Annmarie |e verfasserin |4 aut | |
| 700 | 1 | |a Grayson, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a McDowell, Cliona |e verfasserin |4 aut | |
| 700 | 1 | |a Phair, Glenn |e verfasserin |4 aut | |
| 700 | 1 | |a Plummer, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Storey, Dawn |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a McMullan, Ronan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health technology assessment (Winchester, England) |d 1998 |g 28(2024), 14 vom: 09. März, Seite 1-101 |w (DE-627)NLM093582129 |x 2046-4924 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:14 |g day:09 |g month:03 |g pages:1-101 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3310/RGTP7112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 14 |b 09 |c 03 |h 1-101 | ||